Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study

被引:1
|
作者
Nalwanga, Damalie [1 ,2 ]
Musiime, Victor [1 ,3 ]
Bangirana, Paul [4 ]
Nishiguchi, Erika Phelps [5 ]
Kiggwe, Andrew [2 ]
Ssesanga, Titus [3 ]
Ssenkusu, John M. [6 ]
Musoke, Philippa [1 ]
Cusick, Sarah E. [7 ]
机构
[1] Makerere Univ, Sch Med, Dept Paediat & Child Hlth, Coll Hlth Sci, POB 7072, Kampala, Uganda
[2] Makerere Univ Lung Inst, POB 7749, Kampala, Uganda
[3] Joint Clin Res Ctr, Res Dept, POB 10005, Kampala, Uganda
[4] Makerere Univ, Sch Med, Dept Psychiat, Coll Hlth Sci, POB 7072, Kampala, Uganda
[5] Univ Washington, Dept Paediat, Div Dev Behav Paediat, Seattle, WA 98195 USA
[6] Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Hlth Sci, POB 7072, Kampala, Uganda
[7] Univ Minnesota, Dept Paediat, Minneapolis, MN USA
基金
美国国家卫生研究院;
关键词
Neurocognitive function; Children; HIV; ART; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE IMPAIRMENT; NAIVE; DEFICITS; OUTCOMES; CARE; ART;
D O I
10.1186/s12887-021-02676-2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background HIV infection is associated with significant neurocognitive deficits making maximization of cognitive function among children receiving antiretroviral therapy (ART) a public health imperative. Non-protease inhibitors (non-PIs) achieve higher drug levels in the cerebral spinal fluid (CSF) compared to PIs, potentially leading to better neurocognitive function by reducing CSF viral load and inflammation. ART that maximises children's neurodevelopment and school achievement could result in improved quality of life and productivity as adults, but little research to date has examined whether non-PI ART is associated with better neurocognitive outcomes. We compared the neurocognitive function between children living with HIV receiving PI-based and non PI-based ART. Methods We recruited a consecutive sample of clinically stable Ugandan children living with HIV aged 5-12 years who received PI-based or non PI-based ART for >= 1 year (viral load < 1000 copies). Neurocognitive function was assessed using the Kaufman Assessment Battery for Children, the Test of Variables of Attention, and Bruininks-Oseretsky Test of Motor Proficiency. Age-adjusted neurocognitive z-scores for the two groups were compared using linear regression models in STATA version 13. The Hommel's method was used to adjust for multiple testing. Results We enrolled 76 children living with HIV; 34 on PI ART and 42 on non-PI ART. Mean (+/- SD) age was greater in the non-PI vs. PI group (9.5 +/- 1.9 vs. 8.5 +/- 2.0) years (p = 0.03). Children in the non-PI group had lower socioeconomic scores (5.7 +/- 3.3 vs. 7.4 +/- 2.8, p = 0.02). There was no difference in neurocognitive function between the groups (adjusted p > 0.05) for KABC and TOVA. Children in the PI group had better total BOT scores than their counterparts (46.07 +/- 1.40) vs. 40.51 (1.24), p = 0.03). Conclusions We detected no difference in neurocognitive function among children on PI and non PI-based ART therapy based on KABC and TOVA tests. Children on PI based ART had better motor function than their counterparts. We recommend a prospective study with a larger sample size.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] The Impact of Protease Inhibitor-Based Antiretroviral Regimens On Renal Transplant Outcomes in HIV-Infected Recipients.
    Sparkes, T.
    Manitpisitkul, W.
    Masters, B.
    Pickard, M.
    Amoroso, A.
    Davis, C.
    Mavanur, M.
    Bartlett, S.
    Haririan, A.
    TRANSPLANTATION, 2014, 98 : 187 - 188
  • [22] Evaluation of Lipid Profile and Intima Media Thickness in Antiretroviral-Experienced HIV-Infected Patients Treated with Protease Inhibitor-Based Regimens versus Protease Inhibitor-Sparing Regimens
    Martini, Salvatore
    Pisaturo, Mariantonietta
    Russo, Antonio
    Palamone, Maria Grazia
    Russo, Maria Teresa
    Zollo, Verdiana
    Maggi, Paolo
    Coppola, Nicola
    PATHOGENS, 2023, 12 (07):
  • [23] Paired perhipheral blood and genital tract cytokine and chemokine levels with non-protease inhibitor based antiretrovirals in HIV infected women
    Wanchu, Ajay
    Sachdeva, Ravinder Kaur
    Pallikkuth, Suresh
    Bagga, Rashmi
    Malla, Nancy
    Sharma, Meera
    CYTOKINE, 2008, 43 (03) : 251 - 251
  • [24] Neurological and neurocognitive function of HIV-infected children commenced on antiretroviral therapy
    Smith, Lara
    Adnams, Colleen
    Eley, Brian
    SOUTH AFRICAN JOURNAL OF CHILD HEALTH, 2008, 2 (03) : 108 - 113
  • [25] Tipranavir:: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
    de Mendoza, Carmen
    Morello, Judit
    Garcia-Gasco, Pilar
    Rodriguez-Novoa, Sonia
    Soriano, Vincent
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (06) : 839 - 850
  • [26] Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
    Pensieroso, Simone
    Romiti, Maria Luisa
    Palma, Paolo
    Castelli-Gattinara, Guido
    Bernardi, Stefania
    Freda, Elio
    Rossi, Paolo
    Cancrini, Caterina
    AIDS, 2006, 20 (14) : 1893 - 1896
  • [27] Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens
    Ferretti, Francesca
    Mackie, Nicola E.
    Singh, Gurmit Kaur Jagjit
    Fox, Julie
    Kaye, Steve
    McClure, Myra O.
    Taylor, Graham
    Boffito, Marta
    HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 107 - 110
  • [28] Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment
    Ounjaijean, Sakaewan
    Kulprachakarn, Kanokwan
    Aurpibul, Linda
    Kaewpoowat, Quanhathai
    Boonyapranai, Kongsak
    Chaiwarith, Romanee
    Arwon, Supapong
    Supparatpinyo, Khuanchai
    Rerkasem, Kittipan
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (02): : 289 - 296
  • [29] Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children
    Buchacz, K
    Cervia, JS
    Lindsey, JC
    Hughes, MD
    Seage, GR
    Dankner, WM
    Oleske, JM
    Moye, J
    PEDIATRICS, 2001, 108 (04) : E72
  • [30] Antiretroviral Regimens Containing a Single Protease Inhibitor Increase Risk of Virologic Failure in Young HIV-infected Children
    Walters, Elisabetta
    Reichmuth, Kirsten
    Dramowski, Angela
    Marais, Ben J.
    Cotton, Mark F.
    Rabie, Helena
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (04) : 361 - 363